Aug. 6, 2020: Recent trends in drug interaction rates; integrase inhibitors and cardiac event risk; a deep dive into HIV drug resistance in Florida; frailty symptoms and neurocognitive disorders amidst high CD4 counts.
The international news story that broke at AIDS 2020, explained by the lead researcher.
This Champion of Community’s Role in Clinical Trials Reflects on 40 Years of Fighting Medical Mistrust And Research Neglect
Wakefield retires from the HIV Vaccine Trials Network after 20 years of service.
July 30, 2020: HIV prevention shortfalls among adolescents of color; PrEP use among trans people; PrEP information gaps among women of color; the case for vacation-based (a.k.a. episodic) PrEP.
Richard Jefferys of Treatment Action Group discusses the pipeline for new modalities being explored for treatment, PrEP, vaccine, and cure.
July 16, 2020: Starting HIV treatment during hospitalization for people who use drugs; type of substance use affects viral suppression odds; benefits of a cross-disciplinary medical support team; does STI recency dictate PrEP necessity for women?
COVID-19 or no, there was still plenty to learn at this year's virtual conference, including for U.S. clinicians seeking to improve the care and treatment they provide to their patients living with HIV.
July 9, 2020: Abysmal HIV testing rates in U.S. ambulatory care settings; STI testing frequency in PrEP users; trends in U.S. PrEP uptake; integrating opioid therapy with HCV care in people who inject drugs.
These studies presented at AIDS 2020 explore the benefits and challenges.
July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.